Nicola Silvestris

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1348118/publications.pdf

Version: 2024-02-01

287	7,357	53794	114465
papers	citations	45 h-index	63 g-index

309	309	309	11527
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. Journal of Gastrointestinal Cancer, 2022, 53, 289-298.	1.3	6
2	Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis. Clinical and Experimental Medicine, 2022, 22, 65-74.	3.6	41
3	Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. Journal of Chemotherapy, 2022, 34, 123-132.	1.5	1
4	Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 1261-1268.	2.8	12
5	Identification of early diagnostic biomarkers via WGCNA in gastric cancer. Biomedicine and Pharmacotherapy, 2022, 145, 112477.	5.6	25
6	Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study. Biomedicine and Pharmacotherapy, 2022, 145, 112370.	5.6	10
7	Immunotherapy of cancer in single-cell RNA sequencing era: A precision medicine perspective. Biomedicine and Pharmacotherapy, 2022, 146, 112558.	5.6	10
8	Exploiting systems biology to investigate the gene modules and drugs in ovarian cancer: A hypothesis based on the weighted gene co-expression network analysis. Biomedicine and Pharmacotherapy, 2022, 146, 112537.	5.6	19
9	The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. Biomedicine and Pharmacotherapy, 2022, 146, 112516.	5.6	38
10	The cross-talk between tumor-associated macrophages and tumor endothelium: Recent advances in macrophage-based cancer immunotherapy. Biomedicine and Pharmacotherapy, 2022, 146, 112588.	5.6	14
11	Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. Critical Reviews in Oncology/Hematology, 2022, 169, 103572.	4.4	12
12	Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Critical Reviews in Oncology/Hematology, 2022, 169, 103571.	4.4	17
13	The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies. Critical Reviews in Oncology/Hematology, 2022, 169, 103567.	4.4	26
14	Prediction and validation of GUCA2B as the hub-gene in colorectal cancer based on co-expression network analysis: In-silico and in-vivo study. Biomedicine and Pharmacotherapy, 2022, 147, 112691.	5.6	7
15	Microfluidic-Assisted Preparation of Targeted pH-Responsive Polymeric Micelles Improves Gemcitabine Effectiveness in PDAC: In Vitro Insights. Cancers, 2022, 14, 5.	3.7	12
16	Editorial: The Effect of the COVID-19 Pandemic on Cancer Patients and Healthcare. Frontiers in Oncology, 2022, 12, 859903.	2.8	0
17	â€œPureâ€•hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 41-47.	2.8	6
18	Identification of Common and Distinct Pathways in Inflammatory Bowel Disease and Colorectal Cancer: A Hypothesis Based on Weighted Gene Co-Expression Network Analysis. Frontiers in Genetics, 2022, 13, 848646.	2.3	6

#	Article	IF	Citations
19	The regulatory role of autophagy-related miRNAs in lung cancer drug resistance. Biomedicine and Pharmacotherapy, 2022, 148, 112735.	5.6	26
20	Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer. Critical Reviews in Oncology/Hematology, 2022, 173, 103657.	4.4	6
21	The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials. Critical Reviews in Oncology/Hematology, 2022, 173, 103674.	4.4	17
22	Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy. Journal of Chemotherapy, 2022, 34, 543-549.	1.5	1
23	The Basis and Advances in Clinical Application of Cytomegalovirus-Specific Cytotoxic T Cell Immunotherapy for Glioblastoma Multiforme. Frontiers in Oncology, 2022, 12, 818447.	2.8	10
24	Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy. Molecules, 2022, 27, 3545.	3.8	1
25	Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas. Human Pathology, 2022, 128, 124-133.	2.0	6
26	Varied functions of immune checkpoints during cancer metastasis. Cancer Immunology, Immunotherapy, 2021, 70, 569-588.	4.2	14
27	From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past. Frontiers in Immunology, 2021, 12, 623639.	4.8	22
28	Silencing ZEB2 Induces Apoptosis and Reduces Viability in Glioblastoma Cell Lines. Molecules, 2021, 26, 901.	3.8	3
29	miR-34a and miR-200c Have an Additive Tumor-Suppressive Effect on Breast Cancer Cells and Patient Prognosis. Genes, 2021, 12, 267.	2.4	24
30	The Role of Laparoscopic Surgery in Localized Pancreatic Neuroendocrine Tumours. Current Treatment Options in Oncology, 2021, 22, 27.	3.0	4
31	The Regulatory Cross-Talk between microRNAs and Novel Members of the B7 Family in Human Diseases: A Scoping Review. International Journal of Molecular Sciences, 2021, 22, 2652.	4.1	11
32	Arginase 1 (Arg1) as an Up-Regulated Gene in COVID-19 Patients: A Promising Marker in COVID-19 Immunopathy. Journal of Clinical Medicine, 2021, 10, 1051.	2.4	34
33	Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era. Cancers, 2021, 13, 1906.	3.7	6
34	Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment. Biomedicines, 2021, 9, 373.	3.2	55
35	From Oncogenic Signaling Pathways to Single-Cell Sequencing of Immune Cells: Changing the Landscape of Cancer Immunotherapy. Molecules, 2021, 26, 2278.	3.8	31
36	Prospective Observational COVID-19 Screening and Monitoring of Asymptomatic Cancer Center Health-Care Workers with a Rapid Serological Test. Diagnostics, 2021, 11, 975.	2.6	3

#	Article	IF	Citations
37	The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment. Vaccines, 2021, 9, 532.	4.4	65
38	A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index. Journal of Gastrointestinal Cancer, 2021, , 1.	1.3	0
39	The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead. Frontiers in Immunology, 2021, 12, 676181.	4.8	32
40	Cytotoxic T-Lymphocyte Antigen-4 in Colorectal Cancer: Another Therapeutic Side of Capecitabine. Cancers, 2021, 13, 2414.	3.7	58
41	The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy. Biomedicine and Pharmacotherapy, 2021, 137, 111364.	5.6	21
42	PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines. Biomedicine and Pharmacotherapy, 2021, 138, 111436.	5.6	30
43	Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/SocietÃ Italiana Endocrinologia (SIE)/SocietÃ Italiana Farmacologia (SIF) multidisciplinary consensus position paper. ESMO Open, 2021, 6, 100153.	4.5	13
44	TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. Cancers, 2021, 13, 2839.	3.7	31
45	A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy. Acta OncolÃ³gica, 2021, 60, 1317-1324.	1.8	2
46	A Systematic Review to Clarify the Prognostic Values of CD44 and CD44+CD24- Phenotype in Triple-Negative Breast Cancer Patients: Lessons Learned and The Road Ahead. Frontiers in Oncology, 2021, 11, 689839.	2.8	9
47	Weighted Gene Co-Expression Network Analysis Combined with Machine Learning Validation to Identify Key Modules and Hub Genes Associated with SARS-CoV-2 Infection. Journal of Clinical Medicine, 2021, 10, 3567.	2.4	30
48	Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. Biomedicines, 2021, 9, 1075.	3.2	46
49	A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery. Genes, 2021, 12, 1206.	2.4	35
50	COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial. Frontiers in Immunology, 2021, 12, 704110.	4.8	22
51	A Systematic Review of the Tumor-Infiltrating CD8+ T-Cells/PD-L1 Axis in High-Grade Glial Tumors: Toward Personalized Immuno-Oncology. Frontiers in Immunology, 2021, 12, 734956.	4.8	4
52	The Prognostic Value of CD133 in Predicting the Relapse and Recurrence Pattern of High-Grade Gliomas on MRI: A Meta-Analysis. Frontiers in Oncology, 2021, 11, 722833.	2.8	9
53	A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers. International Journal of Molecular Sciences, 2021, 22, 10389.	4.1	14
54	The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM-SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies. Critical Reviews in Oncology/Hematology, 2021, 165, 103436.	4.4	40

#	Article	IF	Citations
55	Genomic characterization of hepatoid tumors: context matters. Human Pathology, 2021, 118, 30-41.	2.0	9
56	Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints. Life Sciences, 2021, 282, 119826.	4.3	25
57	A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery. Biomedicine and Pharmacotherapy, 2021, 143, 112213.	5.6	21
58	Hepatocellular Cancer. UNIPA Springer Series, 2021, , 689-706.	0.1	2
59	The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment. International Journal of Molecular Sciences, 2021, 22, 10719.	4.1	36
60	Cholangiocarcinoma: new perspectives for new horizons. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1367-1383.	3.0	13
61	PD-L1 and Notch as novel biomarkers in pancreatic sarcomatoid carcinoma: a pilot study. Expert Opinion on Therapeutic Targets, 2021, 25, 1007-1016.	3.4	13
62	Photodynamic Therapy with Zinc Phthalocyanine Inhibits the Stemness and Development of Colorectal Cancer: Time to Overcome the Challenging Barriers?. Molecules, 2021, 26, 6877.	3.8	6
63	A Promising Role of TGF-Î² Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report. Medicina (Lithuania), 2021, 57, 1241.	2.0	3
64	What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?. EBioMedicine, 2021, 74, 103733.	6.1	1
65	A Systematic Review on PD-1 Blockade and PD-1 Gene-Editing of CAR-T Cells for Glioma Therapy: From Deciphering to Personalized Medicine. Frontiers in Immunology, 2021, 12, 788211.	4.8	5
66	Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy. Life, 2021, 11, 1355.	2.4	8
67	The prognostic nutritional index predicts survival and response to firstâ€line chemotherapy in advanced biliary cancer. Liver International, 2020, 40, 704-711.	3.9	42
68	NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer. Frontiers in Oncology, 2020, 10, 1587.	2.8	19
69	Bioinformatics-Based Identification of a circRNA-miRNA-mRNA Axis in Esophageal Squamous Cell Carcinomas. Journal of Oncology, 2020, 2020, 1-9.	1.3	7
70	Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/SocietÃ Italiana Farmacologia (SIF) multidisciplinary consensus position paper. Critical Reviews in Oncology/Hematology, 2020, 154, 103066.	4.4	7
71	The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers. International Journal of Molecular Sciences, 2020, 21, 5034.	4.1	30
72	Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?. International Journal of Molecular Sciences, 2020, 21, 8305.	4.1	58

#	Article	IF	Citations
73	Targeting TGF-Î²-Mediated SMAD Signaling Pathway via Novel Recombinant Cytotoxin II: A Potent Protein from Naja naja oxiana Venom in Melanoma. Molecules, 2020, 25, 5148.	3.8	10
74	Coronavirus Disease 2019: A Brief Review of the Clinical Manifestations and Pathogenesis to the Novel Management Approaches and Treatments. Frontiers in Oncology, 2020, 10, 572329.	2.8	7
75	On the Management of Drug Interactions in the Course of Concomitant Treatments for COVID-19 and Antineoplastic Agents. Frontiers in Oncology, 2020, 10, 1340.	2.8	3
76	Laparoscopic vs. open mesorectal excision for rectal cancer: Are these approaches still comparable? A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0235887.	2.5	17
77	Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection. Frontiers in Oncology, 2020, 10, 1292.	2.8	2
78	Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study. Diagnostics, 2020, 10, 704.	2.6	54
79	Hydroxy-Propil-Î²-Cyclodextrin Inclusion Complexes of two Biphenylnicotinamide Derivatives: Formulation and Anti-Proliferative Activity Evaluation in Pancreatic Cancer Cell Models. International Journal of Molecular Sciences, 2020, 21, 6545.	4.1	4
80	MicroRNAs and lncRNAsâ€"A New Layer of Myeloid-Derived Suppressor Cells Regulation. Frontiers in Immunology, 2020, 11, 572323.	4.8	17
81	Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside. International Journal of Molecular Sciences, 2020, 21, 3054.	4.1	41
82	Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. Clinical Cancer Research, 2020, 26, 4485-4493.	7.0	13
83	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. PLoS ONE, 2020, 15, e0232449.	2.5	29
84	Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. Annals of Translational Medicine, 2020, 8, 482-482.	1.7	101
85	Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. Journal of Experimental and Clinical Cancer Research, 2020, 39, 95.	8.6	147
86	Neutrophils, Crucial, or Harmful Immune Cells Involved in Coronavirus Infection: A Bioinformatics Study. Frontiers in Genetics, 2020, 11, 641.	2.3	71
87	Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma. Journal of Clinical Medicine, 2020, 9, 1594.	2.4	49
88	Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. International Journal of Cancer, 2020, 147, 3177-3188.	5.1	17
89	Expression and characterization of a novel recombinant cytotoxin II from Naja naja oxiana venom: A potential treatment for breast cancer. International Journal of Biological Macromolecules, 2020, 162, 1283-1292.	7.5	5
90	A moonshot approach toward the management of cancer patients in the COVID-19 time: what have we learned and what could the Italian network of cancer centers (Alliance Against Cancer, ACC) do after the pandemic wave?. Journal of Experimental and Clinical Cancer Research, 2020, 39, 109.	8.6	9

#	Article	IF	Citations
91	Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM). Cancers, 2020, 12, 1681.	3.7	20
92	Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB Technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines. Cancers, 2020, 12, 1729.	3.7	26
93	Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials. International Journal of Molecular Sciences, 2020, 21, 4427.	4.1	67
94	Bortezomib Treatment Modulates Autophagy in Multiple Myeloma. Journal of Clinical Medicine, 2020, 9, 552.	2.4	40
95	Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. Targeted Oncology, 2020, 15, 115-126.	3.6	15
96	Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death. Cancers, 2020, 12, 1047.	3.7	95
97	MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers. International Journal of Molecular Sciences, 2020, 21, 2578.	4.1	35
98	COVID-19 Pandemic and the Crisis of Health Systems: The Experience of the Apulia Cancer Network and of the Comprehensive Cancer Center Istituto Tumori â€œGiovanni Paolo Iiâ€•of Bari. International Journal of Environmental Research and Public Health, 2020, 17, 2763.	2.6	12
99	COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?. Frontiers in Oncology, 2020, 10, 734.	2.8	38
100	Rapid Serological Assays and SARS-CoV-2 Real-Time Polymerase Chain Reaction Assays for the Detection of SARS-CoV-2: Comparative Study. Journal of Medical Internet Research, 2020, 22, e19152.	4.3	20
101	Biomarker phenotyping drives clinical management in axillary sentinel node: A retrospective study on women with primary breast cancer in 2002. Oncology Letters, 2020, 20, 2469-2476.	1.8	3
102	Independent Negative Prognostic Role of TCF1 Expression within the Wnt/Î²-Catenin Signaling Pathway in Primary Breast Cancer Patients. Cancers, 2019, 11, 1035.	3.7	12
103	Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study. Cancers, 2019, 11, 942.	3.7	66
104	Systematic Review of Irreversible Electroporation Role in Management of Locally Advanced Pancreatic Cancer. Cancers, 2019, 11, 1718.	3.7	27
105	Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib. Medicina (Lithuania), 2019, 55, 707.	2.0	53
106	How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis. Cancers, 2019, 11, 1189.	3.7	4
107	Sorafenib in patients with hepatocellular carcinoma: 10 years of real life. Annals of Oncology, 2019, 30, iv57.	1.2	0
108	Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. Gastrointestinal Tumors, 2019, 6, 92-107.	0.7	22

#	Article	IF	Citations
109	Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities. Cancers, 2019, 11, 1419.	3.7	54
110	Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview. Cancers, 2019, 11, 1270.	3.7	25
111	Should Tumor Infiltrating Lymphocytes, Androgen Receptor, and FOXA1 Expression Predict the Clinical Outcome in Triple Negative Breast Cancer Patients?. Cancers, 2019, 11, 1393.	3.7	13
112	Intratumoral, rather than stromal, CD8+ T cells could be a potential negative prognostic marker in invasive breast cancer patients. Translational Oncology, 2019, 12, 585-595.	3.7	36
113	Prognostic Role of High-Grade Tumor Budding in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis with a Focus on Epithelial to Mesenchymal Transition. Cancers, 2019, 11, 113.	3.7	45
114	<p>Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.7	28
115	Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. Cancers, 2019, 11, 749.	3.7	4
116	Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societaâ€™ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper. Critical Reviews in Oncology/Hematology, 2019, 140, 39-51.	4.4	11
117	THU-448-Multicentric prospettive study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: Interim analysis of INNOVATE study. Journal of Hepatology, 2019, 70, e356.	3.7	0
118	Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review. Cancers, 2019, 11, 539.	3.7	45
119	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. European Journal of Cancer, 2019, 111, 94-106.	2.8	36
120	Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells. Scientific Reports, 2019, 9, 4099.	3.3	112
121	CAFs and TGF-Î² Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer. Cancers, 2019, 11, 330.	3.7	71
122	The Italian Rare Pancreatic Exocrine Cancer Initiative. Tumori, 2019, 105, 353-358.	1.1	7
123	Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma. European Journal of Clinical Investigation, 2019, 49, e13087.	3.4	33
124	Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimitotic agents for the treatment of Hodgkin Lymphoma. Cancer Letters, 2019, 445, 1-10.	7.2	7
125	Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. Journal of Geriatric Oncology, 2019, 10, 591-597.	1.0	6
126	Mast cells and angiogenesis in pancreatic ductal adenocarcinoma. Clinical and Experimental Medicine, 2018, 18, 319-323.	3.6	30

#	Article	IF	Citations
127	Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential. Expert Review of Gastroenterology and Hepatology, 2018, 12, 471-478.	3.0	5
128	Bone metastases in biliary cancers: A multicenter retrospective survey. Journal of Bone Oncology, 2018, 12, 33-37.	2.4	5
129	The role of inflammatory cytokines and tumor associated macrophages (TAMs) in microenvironment of pancreatic cancer. Cytokine and Growth Factor Reviews, 2018, 39, 46-61.	7.2	90
130	Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets. Expert Opinion on Therapeutic Targets, 2018, 22, 453-461.	3.4	15
131	CAPTEM or FOLFIRI as second-line therapy in neuroendocrine carcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study). Annals of Oncology, 2018, 29, viii477-viii478.	1.2	0
132	Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations. Annals of Oncology, 2018, 29, viii261-viii262.	1.2	0
133	The role of adjuvant therapy in resectable SBA: A different clinicians attitude with a relevant impact on outcome. Annals of Oncology, 2018, 29, viii264.	1.2	0
134	Focus on pancreatic cancer. Digestive and Liver Disease, 2018, 50, 1272-1273.	0.9	0
135	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. Tumori, 2018, 104, 476-479.	1.1	14
136	Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors. Pancreas, 2018, 47, 759-771.	1.1	29
137	NHERF1 and tumor microenvironment: a new scene in invasive breast carcinoma. Journal of Experimental and Clinical Cancer Research, 2018, 37, 96.	8.6	16
138	Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers. Translational Oncology, 2018, 11, 825-835.	3.7	45
139	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. Oncology, 2018, 95, 344-352.	1.9	11
140	Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. Scientific Reports, 2017, 7, 42499.	3.3	30
141	Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Critical Reviews in Oncology/Hematology, 2017, 111, 152-165.	4.4	28
142	Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?. Critical Reviews in Oncology/Hematology, 2017, 115, 1-12.	4.4	26
143	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. Cancer Medicine, 2017, 6, 1493-1499.	2.8	11
144	Validation of a simple scoring system to predict sorafenib effectiveness in patients with hepatocellular carcinoma. Digestive and Liver Disease, 2017, 49, e42.	0.9	0

#	Article	IF	Citations
145	Immunotherapy for colorectal cancer: where are we heading?. Expert Opinion on Biological Therapy, 2017, 17, 709-721.	3.1	85
146	Immunotherapy for gastric cancers: emerging role and future perspectives. Expert Review of Clinical Pharmacology, 2017, 10, 609-619.	3.1	33
147	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. Gastric Cancer, 2017, 20, 825-833.	5.3	32
148	Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. European Journal of Cancer, 2017, 86, 106-114.	2.8	76
149	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. Oncologist, 2017, 22, 1463-1469.	3.7	27
150	Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. Targeted Oncology, 2017, 12, 795-803.	3.6	23
151	Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the SocietÃ Italiana di Nefrologia (SIN). ESMO Open, 2017, 2, e000167.	4.5	27
152	Immunotherapeutic approaches for hepatocellular carcinoma. Oncotarget, 2017, 8, 33897-33910.	1.8	50
153	Targeting Angiogenesis in Biliary Tract Cancers: An Open Option. International Journal of Molecular Sciences, 2017, 18, 418.	4.1	47
154	Prognostic factors in unresectable biliary tract cancer: a GICO (Gruppo Italiano COlangiocarcinoma) retrospective analysis. Annals of Oncology, 2017, 28, vi48.	1.2	1
155	Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research. Journal of Experimental and Clinical Cancer Research, 2017, 36, 128.	8.6	18
156	Second-line treatment efficacy in elderly vs. non-elderly advanced gastric cancer patients: an Italian multicentre real-world study. Annals of Oncology, 2017, 28, vi45.	1.2	0
157	Grape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicity. Oncotarget, 2017, 8, 50845-50863.	1.8	9
158	Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review. Oncotarget, 2017, 8, 66699-66708.	1.8	11
159	Hierarchical clustering analysis identifies metastatic colorectal cancers patients with more aggressive phenotype. Oncotarget, 2017, 8, 87782-87794.	1.8	4
160	Angiogenesis in adenosquamous cancer of pancreas. Oncotarget, 2017, 8, 95773-95779.	1.8	19
161	Molecular classifications of gastric cancers: Novel insights and possible future applications. World Journal of Gastrointestinal Oncology, 2017, 9, 194.	2.0	46
162	Metformin effects on clinical outcome in advanced HCC patients receiving sorafenib: Validation study.. Journal of Clinical Oncology, 2017, 35, e15684-e15684.	1.6	0

#	Article	IF	Citations
163	Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma. OncoTargets and Therapy, 2016, Volume 9, 4681-4686.	2.0	9
164	In Reply. Oncologist, 2016, 21, e5-e6.	3.7	0
165	HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. Oncotarget, 2016, 7, 69060-69074.	1.8	29
166	Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue. Oncotarget, 2016, 7, 58649-58658.	1.8	76
167	Prolonged Drainage and Intrapericardial Bleomycin Administration for Cardiac Tamponade Secondary to Cancer-Related Pericardial Effusion. Medicine (United States), 2016, 95, e3273.	1.0	18
168	The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. Targeted Oncology, 2016, 11, 593-603.	3.6	14
169	Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. Oncologist, 2016, 21, 600-607.	3.7	24
170	The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. Scientific Reports, 2016, 6, 24136.	3.3	22
171	Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance. Cancer Biology and Therapy, 2016, 17, 400-406.	3.4	67
172	Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. Digestive and Liver Disease, 2016, 48, 231-241.	0.9	74
173	Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Critical Reviews in Oncology/Hematology, 2016, 98, 309-324.	4.4	35
174	Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1Î±â€"Final results of the ALICE-2 study.. Journal of Clinical Oncology, 2016, 34, 280-280.	1.6	13
175	Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. Oncotarget, 2016, 7, 67142-67149.	1.8	91
176	Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group. Oncotarget, 2016, 7, 15243-15251.	1.8	26
177	Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. World Journal of Gastroenterology, 2016, 22, 6287.	3.3	8
178	Prognostic factors in 868 advanced gastric cancer patients exposed to second-line therapy.. Journal of Clinical Oncology, 2016, 34, e15553-e15553.	1.6	0
179	P-115 Transarterial Chemo-Embolization (TACE) and Radio-Embolization (TARE) in the combined modality treatment of advanced biliary tract cancer (aBTC): evaluation of feasibility and activity. Annals of Oncology, 2015, 26, iv32.	1.2	1
180	Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. Journal of Experimental and Clinical Cancer Research, 2015, 34, 156.	8.6	54

#	Article	IF	Citations
181	MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?. Oncotarget, 2015, 6, 23323-23341.	1.8	65
182	Cancer survivorship. Current Opinion in Oncology, 2015, 27, 351-357.	2.4	41
183	Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. Expert Opinion on Biological Therapy, 2015, 15, 155-162.	3.1	27
184	MiRNAs modulate gastric cancer drug response by affecting hypoxia signaling. Annals of Oncology, 2015, 26, vi99.	1.2	0
185	Metronomic chemotherapy from rationale to clinical studies: A dream or reality?. Critical Reviews in Oncology/Hematology, 2015, 95, 46-61.	4.4	64
186	Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy. Expert Opinion on Drug Safety, 2015, 14, 253-267.	2.4	43
187	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. Journal of Experimental and Clinical Cancer Research, 2015, 34, 10.	8.6	65
188	The distinctive molecular, pathological and clinical characteristics ofBRAF-mutant colorectal tumors. Expert Review of Molecular Diagnostics, 2015, 15, 979-987.	3.1	14
189	The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy. Cancer Biology and Therapy, 2015, 16, 1140-1147.	3.4	12
190	Metastatic gastric cancer in the last two decades: goals achieved and future promises. Future Oncology, 2015, 11, 2633-2636.	2.4	5
191	Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. Expert Opinion on Pharmacotherapy, 2015, 16, 2719-2725.	1.8	66
192	Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?. Expert Opinion on Therapeutic Targets, 2015, 19, 1623-1635.	3.4	58
193	Hospital Admission of Cancer Patients: Avoidable Practice or Necessary Care?. PLoS ONE, 2015, 10, e0120827.	2.5	93
194	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?. Oncotarget, 2015, 6, 24780-24796.	1.8	77
195	Robotic radiosurgery in pancreatic cancer: A systematic review. World Journal of Gastroenterology, 2015, 21, 9420.	3.3	12
196	Effect of metformin on clinical outcome in advanced HCC patients receiving sorafenib.. Journal of Clinical Oncology, 2015, 33, e15156-e15156.	1.6	0
197	LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first line chemotherapy.. Journal of Clinical Oncology, 2015, 33, e15126-e15126.	1.6	0
198	Chemotherapy-Induced Nausea and Vomiting in Italian Cancer Centers: Results of CINVDAY, a Prospective, Multicenter Study. Tumori, 2014, 100, e309-e313.	1.1	0

#	Article	IF	Citations
199	Clinical and Organizational Issues in the Management of Surviving Breast and Colorectal Cancer Patients: Attitudes and Feelings of Medical Oncologists. PLoS ONE, 2014, 9, e101170.	2.5	8
200	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. PLoS ONE, 2014, 9, e105268.	2.5	33
201	Challenges and Opportunities of MicroRNAs in Lymphomas. Molecules, 2014, 19, 14723-14781.	3.8	26
202	CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen. International Journal of Molecular Sciences, 2014, 15, 15767-15777.	4.1	20
203	Clinical Application of MicroRNA Testing in Neuroendocrine Tumors of the Gastrointestinal Tract. Molecules, 2014, 19, 2458-2468.	3.8	47
204	Editorial (Thematic Issue: Targeted Therapies in Upper Gastrointestinal Malignancies). Current Medicinal Chemistry, 2014, 21, 947-947.	2.4	0
205	Does First-Line Therapy Affect the Outcome of Patients with Pancreatic Cancer?. Annals of Oncology, 2014, 25, iv236.	1.2	0
206	Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. Pharmacogenomics, 2014, 15, 1701-1715.	1.3	4
207	Second-line chemotherapy in advanced biliary cancer: the present now will later be past. Annals of Oncology, 2014, 25, 2443-2444.	1.2	2
208	Vaccination for seasonal influenza in patients with cancer: recommendations of the Italian Society of Medical Oncology (AIOM). Annals of Oncology, 2014, 25, 1243-1247.	1.2	28
209	Predictive factors to targeted treatment in gastrointestinal carcinomas. Cancer Biomarkers, 2014, 14, 151-162.	1.7	5
210	Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. British Journal of Cancer, 2014, 110, 2165-2169.	6.4	69
211	Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior?. Supportive Care in Cancer, 2014, 22, 2813-2819.	2.2	12
212	The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment. Molecules, 2014, 19, 6393-6406.	3.8	56
213	Role of MicroRNA in Response to Ionizing Radiations: Evidences and Potential Impact on Clinical Practice for Radiotherapy. Molecules, 2014, 19, 5379-5401.	3.8	63
214	Target Therapies in Pancreatic Carcinoma. Current Medicinal Chemistry, 2014, 21, 948-965.	2.4	43
215	Expression and prognostic value of VEGFR-2, PDGFR-Î², and c-Met in advanced hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2013, 32, 16.	8.6	86
216	Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Supportive Care in Cancer, 2013, 21, 1313-1319.	2.2	57

#	Article	IF	Citations
217	Synchronous Mandibular and Giant Parieto-occipital Skull Metastasis From Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2013, 11, A26.	4.4	5
218	Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Molecular Oncology, 2013, 7, 308-322.	4.6	54
219	Comment and reply on: Pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens. Expert Opinion on Therapeutic Targets, 2013, 17, 473-475.	3.4	0
220	Coâ€expression of CD133⁺/CD44⁺ in human colon cancer and liver metastasis. Journal of Cellular Physiology, 2013, 228, 408-415.	4.1	45
221	Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence. Critical Reviews in Oncology/Hematology, 2013, 85, 112-120.	4.4	21
222	Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?. Future Oncology, 2013, 9, 1809-1811.	2.4	2
223	Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX. Supportive Care in Cancer, 2013, 21, 2955-2956.	2.2	8
224	Carcinogenesis of Pancreatic Adenocarcinoma: Precursor Lesions. International Journal of Molecular Sciences, 2013, 14, 19731-19762.	4.1	59
225	Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment. Cancer Biology and Therapy, 2013, 14, 467-468.	3.4	5
226	TORCH Study: How Much Longer Should We Continue to Use Erlotinib in Unselected Patients With Nonâ€“Small-Cell Lung Cancer?. Journal of Clinical Oncology, 2013, 31, 288-289.	1.6	4
227	High density of tryptaseâ€positive mast cells in human colorectal cancer: a poor prognostic factor related to proteaseâ€activated receptor 2 expression. Journal of Cellular and Molecular Medicine, 2013, 17, 1025-1037.	3.6	80
228	Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature. Tumori, 2013, 99, e241-e244.	1.1	4
229	Complete Response to Second Line Paclitaxel Every 2 Weeks of Eyelid Kaposi Sarcoma. Ophthalmic Plastic and Reconstructive Surgery, 2013, 29, e114-e115.	0.8	2
230	Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey. PLoS ONE, 2013, 8, e74402.	2.5	56
231	Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey. PLoS ONE, 2013, 8, e83026.	2.5	66
232	Poly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment. Expert Opinion on Therapeutic Targets, 2012, 16, S83-S89.	3.4	8
233	Synthetic Lethality to Overcome Cancer Drug Resistance. Current Medicinal Chemistry, 2012, 19, 3858-3873.	2.4	18
234	Antineoplastic drug-induced bradyarrhythmias. Expert Opinion on Drug Safety, 2012, 11, 739-751.	2.4	10

#	Article	IF	Citations
235	Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Annals of Oncology, 2012, 23, 2072-2077.	1.2	108
236	Combined modality treatments in pancreatic cancer. Expert Opinion on Therapeutic Targets, 2012, 16, S71-S81.	3.4	10
237	Takotsubo Syndrome in a Patient Treated With Sunitinib for Renal Cancer. Journal of Clinical Oncology, 2012, 30, e218-e220.	1.6	34
238	mTOR as a Target of Everolimus in Refractory/Relapsed Hodgkin Lymphoma. Current Medicinal Chemistry, 2012, 19, 945-954.	2.4	11
239	Current status of targeted therapies in advanced gastric cancer. Expert Opinion on Therapeutic Targets, 2012, 16, S29-S34.	3.4	35
240	Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. Expert Opinion on Therapeutic Targets, 2012, 16, S111-S117.	3.4	13
241	Overexpression of nuclear NHERF1 in advanced colorectal cancer: Association with hypoxic microenvironment and tumor invasive phenotype. Experimental and Molecular Pathology, 2012, 92, 296-303.	2.1	40
242	Targeting EGFR in bilio-pancreatic and liver carcinoma. Frontiers in Bioscience - Scholar, 2011, S3, 16-22.	2.1	7
243	Advances in EGFR-directed therapy in head and neck cancer. Frontiers in Bioscience - Scholar, 2011, S3, 454-466.	2.1	10
244	Peripheral Skin Edema as Unusual Toxicity in Three Patients with Advanced Non-small Cell Lung Cancer Treated with Pemetrexed Alone or in Combination with Cisplatin. Journal of Thoracic Oncology, 2011, 6, 1964.	1.1	6
245	Dasatinib: An Anti-Tumour Agent via Src Inhibition. Current Drug Targets, 2011, 12, 563-578.	2.1	93
246	The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy. Current Drug Metabolism, 2011, 12, 713-721.	1.2	17
247	Pharmacokinetic and Metabolism Determinants of Fluoropyrimidines and Oxaliplatin Activity in Treatment of Colorectal Patients. Current Drug Metabolism, 2011, 12, 918-931.	1.2	11
248	Survival prediction and frequency of anticancer treatment in cancer patients hospitalized due to acute conditions. Role of clinical parameters and PaP score. Supportive Care in Cancer, 2011, 19, 1823-1830.	2.2	21
249	Oncosuppressor methylation: A possible key role in colon metastatic progression. Journal of Cellular Physiology, 2011, 226, 1934-1939.	4.1	20
250	Synchronous Presentation of B-Cell Chronic Lymphocytic Leukemia/Small-Cell Lymphoma and Colon Adenocarcinoma Within the Same Mesenteric Lymph Nodes and a Single Liver Metastasis. Journal of Clinical Oncology, 2011, 29, e11-e13.	1.6	8
251	EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Frontiers in Bioscience - Landmark, 2011, 16, 1962.	3.0	42
252	Nti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence. Frontiers in Bioscience - Landmark, 2011, 16, 1973.	3.0	7

#	Article	IF	Citations
253	Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies. Breast, 2010, 19, 214-218.	2.2	11
254	p53 as the main traffic controller of the cell signaling network. Frontiers in Bioscience - Landmark, 2010, 15, 1172.	3.0	12
255	High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. Annals of Oncology, 2010, 21, 1565.	1.2	38
256	Cetuximab plus FOLFOX-4 in Untreated Patients with Advanced Colorectal Cancer: A Gruppo Oncologico dellâ€™Italia Meridionale Multicenter Phase II Study. Oncology, 2010, 79, 415-422.	1.9	16
257	Update on capecitabine alone and in combination regimens in colorectal cancer patients. Cancer Treatment Reviews, 2010, 36, S46-S55.	7.7	15
258	Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?. Cancer Treatment Reviews, 2010, 36, S56-S61.	7.7	103
259	Rapidly Progressive Coma in Leptomeningeal Carcinomatosis From Undiagnosed Bronchioloalveolar Carcinoma. Journal of Clinical Oncology, 2009, 27, e65-e66.	1.6	1
260	Adjuvant Therapy in Colon Cancer. Oncology, 2009, 77, 50-56.	1.9	13
261	KRASmutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue. Expert Opinion on Biological Therapy, 2009, 9, 565-577.	3.1	10
262	The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway. Oncology, 2009, 77, 57-68.	1.9	49
263	The process of truth disclosure: an assessment of the results of information during the diagnostic phase in patients with cancer. Annals of Oncology, 2009, 20, 941-945.	1.2	45
264	Unique Case of Giant Adult Paratesticular Spindle Cell Rhabdomyosarcoma. Urology, 2009, 73, 500-502.	1.0	9
265	The Dark Side of the Moon: The PI3K/PTEN/AKT Pathway in Colorectal Carcinoma. Oncology, 2009, 77, 69-74.	1.9	16
266	Efficacy and Safety of the Combination of Docetaxel (Taxotere®) with Targeted Therapies in the Treatment of Solid Malignancies. Current Drug Targets, 2009, 10, 982-1000.	2.1	5
267	Successful treatment with three-weekly paclitaxel of an anthracycline-refractory classical Kaposi's sarcoma. Anticancer Research, 2009, 29, 675-6.	1.1	4
268	Giant Borderline Phyllodes Tumor of the Breast. Breast Journal, 2008, 14, 203-204.	1.0	0
269	Role of gemcitabine in metastatic breast cancer patients: A short review. Breast, 2008, 17, 220-226.	2.2	47
270	Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer, 2005, 103, 994-999.	4.1	186

#	Article	IF	Citations
271	Lack of Response to Imatinib Mesylate as Second-Line Therapy in a Patient with C-Kit Positive Metastatic Soft Tissue Leiomyosarcoma. Tumori, 2005, 91, 103-103.	1.1	6
272	Present Status and Perspectives in the Treatment of Hormone-Refractory Prostate Cancer. Oncology, 2005, 69, 273-282.	1.9	21
273	A Phase I Study of Capecitabine in Combination with Vinorelbine in Advanced Breast Cancer. Clinical Breast Cancer, 2003, 4, 138-141.	2.4	19
274	Long-Term Follow-Up in Breast Cancer Survivors: A Single Institution Survey. Journal of Women's Health, 2003, 12, 599-600.	3.3	0
275	Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. British Journal of Cancer, 2003, 88, 491-495.	6.4	8
276	Docetaxel in Advanced Gastric Cancer Review of the Main Clinical Trials. Acta OncolÃ³gica, 2003, 42, 693-700.	1.8	22
277	Unusual Response to Second-Line Single-Agent Gemcitabine in Locally Advanced Primary Leiomyosarcoma of the Lung: A Case Report. Journal of Chemotherapy, 2003, 15, 507-509.	1.5	7
278	Breast Cancer Metastatic to the Choroid in a Male Patient Case Report. Tumori, 2003, 89, 333-335.	1.1	4
279	Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer. Annals of Oncology, 2002, 13, 1862-1867.	1.2	6
280	Failure of primary breast cancer neoangiogenesis to predict pattern of distant metastasis. Clinical and Experimental Medicine, 2001, 1, 127-132.	3.6	5
281	The role of letrozole (Femara(R)) in breast cancer therapy: A clinical review. Drugs of Today, 2001, 37, 639.	1.1	5
282	Importance of paraneoplastic papulosquamous disorders in patients with solid tumors. Journal of Chemotherapy, 1999, 11, 237-238.	1.5	0
283	Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells. Clinical and Experimental Immunology, 1998, 114, 179-188.	2.6	25
284	IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activity. International Journal of Clinical and Laboratory Research, 1997, 27, 48-54.	1.0	32
285	Cross-linking of Fas By Antibodies to a Peculiar Domain of gp120 V3 Loop Can Enhance T Cell Apoptosis in HIV-1â€“infected Patients. Journal of Experimental Medicine, 1996, 184, 2287-2300.	8.5	26
286	Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: A phase II trial. Oncology Reports, 0, , .	2.6	1
287	Development of Approaches and Metrics to Measure the Impact and Improve the Clinical Outcomes of Patients With Frailty in the Era of COVID-19. The COMETA Italian Protocol. Frontiers in Oncology, 0, 12, .	2.8	2